INSURING HEALTHCARE WORKERS WHO ADMINISTER PSYCHEDELICS CLINICAL TRIALS
Are you and your staff protected?
The use of psychedelics in a medical setting is experiencing a renaissance. Despite longstanding restrictions on psychedelics dating back to the 1970s, the stigma associated with psychedelics continues to diminish as widespread interest grows larger, and this is due in large part to clinical trials demonstrating their promise in treating a multitude of mental health disorders.
However, in spite of this progress, testing psychedelics effectively and translating the research into treatments is complex and risky.
Partnering with an experienced team that can navigate the complexities of risk exposures facing companies and people involved in psychedelics research and clinical trials is critical, especially in the novel psychedelics research space.
AHT’s professionals have the experience to navigate the rapidly changing psychedelics risk landscape, prepare for managing exposures, and identify the proper coverage to help protect those overseeing the clinical trials for these breakthrough treatments.